TAT 2016
 
Wednesday, March 23, 2016
8:30 am - 9:45 amPlenary Session 9: Drug Development Methodology
Chair: Jean-Charles Soria, Cancer Institute Gustave Roussy
Chair: Lee Ellis, MD Anderson Cancer Center
8:31 am - 8:50 amO9.1 Exosomal DNA in serum for cancer diagnosis and detection of gene mutations
Speaker: Christoph Kahlert, Technical University Dresden
8:50 am - 9:10 amO9.2 Circulating cells and cell-free nucleic acids in cancer treatment monitoring
Speaker: Anton Wellstein, Georgetown University Medical School
9:10 am - 9:30 amO9.3 Value of patient-derived xenografts and organoids in therapy selection
Speaker: Manuel Hidalgo, Spanish National Cancer Research Centre
9:30 am - 9:45 amGeneral discussion
9:45 am - 10:15 amBreak




10:15 am - 12:15 pmPlenary Session 10: Miscellaneous Drugs and Targets (1)
Chair: Anthony Tolcher, South Texas Accelerated Research Therapeutics
Chair: Keith Flaherty, Massachusetts General Hospital
10:16 am - 10:30 amO10.1 A phase 1 study of PF-06647020, an antibody-drug conjugate targeting PTK7, in patients with advanced solid tumors
Speaker: Emiliano Calvo, START Madrid
10:30 am - 10:45 amO10.2 Merging the concepts of compensatory signaling and epigenetic state change in therapeutic resistance
Speaker: Keith Flaherty, Massachusetts General Hospital
10:45 am - 11:00 amO10.3 Inhibiting mutant isocitrate dehydrogenase: Triumphs and challenges
Speaker: Eytan Stein, Memorial Sloan Kettering Cancer Center
11:00 am - 11:15 amO10.4 Phase 1 trial of a first-in-class PFKFB3 inhibitor reveals a novel immunostimulatory mechanism of action
Speaker: Jason Chesney, University of Louisville
11:15 am - 11:30 amO10.5 Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640
Speaker: Manish Patel, Florida Cancer Specialists/SCRI
11:30 am - 11:45 amO10.6 Glutaminase inhibition by CB-839 (Calithera)
Speaker: James Harding, Memorial Sloan Kettering Cancer Center
11:45 am - 12:15 pmGeneral discussion
12:15 pm - 1:00 pmLunch


1:00 pm - 3:00 pmPlenary Session 11: Miscellaneous Drugs and Targets (2)
Chair: Udai Banerji, The Institute of Cancer Research
Chair: Arne Östman, Karolinska Institutet
1:01 pm - 1:20 pmO11.1 Targeting Sleeping Cancer Cells
Speaker: Sridhar Ramaswamy, Massachusetts General Hospital
1:20 pm - 1:45 pmO11.2 Clinical Implications of Intratumour Heterogeneity
Speaker: Charles Swanton, The Francis Crick Institute
1:45 pm - 2:05 pmO11.3 Nuclear export as a target for cancer therapy
Speaker: Giuseppe Giaccone, Georgetown University
2:05 pm - 2:20 pmO11.4 PROTAC BRD4 Degraders Allow a More Effective Therapeutic Strategy than BRD4 Inhibitors
Speaker: James Winkler, Arvinas
2:20 pm - 2:35 pmO11.5 The rich molecular landscape of metastatic biliary tract cancers in the MOSCATO 01 prospective trial
Speaker: Loic Verlingue, Cancer Institute Gustave Roussy
2:35 pm - 2:50 pmO11.6 Novel targeted phosphorylated p68 inhibitor RX-5902 shows activity in triple negative breast cancer
Speaker: Jennifer Diamond, University of Colorado Cancer Center
2:50 pm - 3:05 pmGeneral discussion
3:05 pm - 3:10 pmClosing remarks
Giuseppe Giaccone, Georgetown University